Stock SILO SILO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Silo Pharma, Inc.

Equities

SILO

US82711P2011

Market Closed - Nasdaq
Other stock markets
 21:30:01 10/05/2024 BST 		5-day change 1st Jan Change
1.68 USD -4.55% Intraday chart for Silo Pharma, Inc. -9.19% +16.67%
04-23 Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment CI
04-10 Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
AQ
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment
CI
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University
MT
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
AQ
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.
CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.
CI
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.
CI
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
AQ
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic
CI
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
AQ
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
CI
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
AQ
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
AQ
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
CI
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
AQ
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
CI
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
AQ
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study
CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SILO Stock
  4. News Silo Pharma, Inc.